Replimune Group Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Sush Patel

Chief Executive Officer (CEO)

US$2.6m

Compensación total

Porcentaje del salario del CEO	17.2%
Permanencia del CEO	no data
Participación del CEO	0.04%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	5.9yrs

Actualizaciones recientes de la dirección

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

Replimune: Interesting Developer Of Oncolytic Immunotherapies

Dec 06

Replimune Group EPS misses by $0.02

Nov 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sush Patel en comparación con los beneficios de Replimune Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$210m
Sep 30 2023	n/a	n/a	-US$199m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	US$3m	US$447k	-US$174m
Dec 31 2022	n/a	n/a	-US$157m
Sep 30 2022	n/a	n/a	-US$147m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	US$7m	US$394k	-US$118m

Compensación vs. Mercado: La compensación total ($USD2.60M) de Sush está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Sush ha sido consistente con los resultados de la empresa en el último año.

CEO

Sush Patel (52 yo)

no data

Permanencia

US$2,595,003

Compensación

Dr. Sushil Patel Ph.D. served as the Chief Commercial Officer at Replimune Group, Inc. since May 3, 2021 and serves as its Chief Strategy Officer. He served as the Head of global oncology for lung cancer,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Philip Astley-Sparke	Executive Chairman	9.3yrs	US$3.65m	2.1% $ 8.3m
Sushil Patel	Chief Executive Officer	no data	US$2.60m	0.041% $ 162.6k
Robert Coffin	Founder	no data	US$5.72m	2.82% $ 11.1m
Emily Hill	Chief Financial Officer	less than a year	sin datos	sin datos
Andrew Schwendenman	Chief Accounting Officer & Treasurer	less than a year	sin datos	0.0046% $ 17.9k
Christopher Sarchi	Chief Commercial Officer	1.3yrs	sin datos	0.014% $ 54.5k
Konstantinos Xynos	Chief Medical Officer	1.3yrs	sin datos	0.081% $ 318.4k
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	less than a year	sin datos	sin datos

0.3yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de REPL no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Philip Astley-Sparke	Executive Chairman	9.3yrs	US$3.65m	2.1% $ 8.3m
Robert Coffin	Founder	9.3yrs	US$5.72m	2.82% $ 11.1m
Joseph Slattery	Independent Director	6.5yrs	US$255.96k	0.011% $ 42.8k
Hyam Levitsky	Independent Non-Executive Director	5.9yrs	US$251.96k	0% $ 0
Paolo Pucci	Independent Director	4yrs	US$251.96k	0% $ 0
Kapil Dhingra	Independent Director	6.8yrs	US$252.96k	0% $ 0
Christy Oliger	Independent Director	2.3yrs	US$248.46k	sin datos
Dieter Weinand	Independent Chairman of the Board	5.8yrs	US$371.44k	0% $ 0
Veleka Peeples-Dyer	Independent Director	less than a year	sin datos	sin datos

5.9yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de REPL se considera experimentada (5.9 años de antigüedad promedio).

Replimune Group Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Recent updates

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold US$156k worth of stock

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Chief Operating Officer notifies of intention to sell stock

Replimune: In The 'Buy Zone' Again

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Chief Medical Officer Andrea Pirzkall has left the company

Chief Business Officer exercised options and sold US$587k worth of stock

Chief Operating Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Chief Operating Officer notifies of intention to sell stock

New 90-day low: US$37.63

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Replimune Group EPS misses by $0.03

Chief Business Officer notifies of intention to sell stock

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

Dosing underway in Replimune's early-stage cancer study with gene therapy

Founder notifies of intention to sell stock

Independent Director notifies of intention to sell stock